SYF20d2a4747c4749108c558d8c422a178fRegistry ID: 2024-514026-23-00|UnknownPhase 2
Inhibition of JAK enzymes in early stage joint inflammation
JAK Inhibition in PReclinical Arthritis
Loading search results
JAK Inhibition in PReclinical Arthritis
interventional
N/A
1 country
1
to evaluate the effect of JAK inhibition with baricitinib in preclinical stage of arthritis
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 8, 2024
Actual (reported)Number of patients with development of arthritis at week 48
Number of patients with development of arthritis at week 24
Fulfillment of the ACR/EULAR 2010 RA classification criteria
Ultrasound: number of patients without signs of PD synovitis or PD tenosynovitis at week 24 and week 48 compared to baseline and compared within both groups
Safety: (S)AE
Subjective (SACRAH, sMHQ) and objective (moberg pick up test (MPUT)) hand function
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
BARICITINIB
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
FILM-COATED TABLET
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
BARICITINIB
Named ingredient: baricitinib
View registry recordUniversitaetsklinikum Erlangen AöR
Erlangen, 91054, Germany
Sara Bayat
First Submitted
May 8, 2024
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
Contact the study team to confirm eligibility.